Search

Your search keyword '"van der Meijden, Edith D."' showing total 2 results
Start Over Author "van der Meijden, Edith D." Journal european journal of immunology
2 results on '"van der Meijden, Edith D."'

1. Natural T-cell ligands that are created by genetic variants can be transferred between cells by extracellular vesicles

Author

Kremer, Anita N, Zonneveld, Marijke I, Kremer, Andreas E, van der Meijden, Edith D, Falkenburg, J H Frederik, Wauben, Marca H M, Nolte-'t Hoen, Esther N M, Griffioen, Marieke, LS Celbiologie-Algemeen, dB&C I&I, Sub Immunopharmacology, LS Celbiologie-Algemeen, dB&C I&I, Sub Immunopharmacology, and Academic Medical Center

Subjects
CD4-Positive T-Lymphocytes, 0301 basic medicine, T cell, Adaptive immunity, Immunology, Antigen presentation, T cells, Antigen-Presenting Cells, Human leukocyte antigen, Biology, Ligands, Tumor Immunity, Epitope, Minor Histocompatibility Antigens, 03 medical and health sciences, Immune system, Antigen, Neoplasms, medicine, Humans, Immunology and Allergy, Basic, Antigens, Research Articles, MHC class II, Histocompatibility Antigens Class II, Genetic Variation, T-Lymphocytes, Helper-Inducer, Extracellular vesicles, Acquired immune system, Cell biology, Phosphotransferases (Alcohol Group Acceptor), Focal Adhesion Kinase 2, 030104 developmental biology, medicine.anatomical_structure, biology.protein, Research Article|Basic, HeLa Cells
Abstract

CD4 T-cells play a central role as helper cells in adaptive immunity. Presentation of exogenous antigens in MHC class II by professional antigen-presenting cells is a crucial step in induction of specific CD4 T-cells in adaptive immune responses. For efficient induction of immunity against intracellular threats such as viruses or malignant transformations, antigens from HLA class II-negative infected or transformed cells need to be transferred to surrounding antigen-presenting cells to allow efficient priming of naive CD4 T-cells. Here we show indirect antigen presentation for a subset of natural HLA class II ligands that are created by genetic variants and demonstrated that (neo)antigens can be transferred between cells by extracellular vesicles. Intercellular transfer by extracellular vesicles was not dependent on the T-cell epitope, but rather on characteristics of the full-length protein. This mechanism of (neo)antigen transfer from HLA class II-negative cells to surrounding antigen-presenting cells may play a crucial role in induction of anti-tumor immunity. This article is protected by copyright. All rights reserved.

Published
2018

2. Successful treatment of COVID‐19 infection with convalescent plasma in B‐cell‐depleted patients may promote cellular immunity.

Author

Kremer, Andreas E., Kremer, Anita N., Willam, Carsten, Völkl, Simon, Verhagen, Johan, Achenbach, Susanne, van der Meijden, Edith D., Lang, Vanessa, Aigner, Michael, Maier, Clara, Tenbusch, Matthias, Korn, Klaus, Lutzny‐Geier, Gloria, Spoerl, Silvia, Strauß, Richard, Vetter, Marcel, Überla, Klaus, Neurath, Markus F., Mackensen, Andreas, and Schiffer, Mario

Subjects
CONVALESCENT plasma, COVID-19, COVID-19 treatment, RITUXIMAB, CELLULAR immunity, IMMUNOGLOBULIN producing cells
Abstract

Treatment with convalescent plasma has been shown to be safe in coronavirus disease in 2019 (COVID‐19) infection, although efficacy reported in immunocompetent patients varies. Nevertheless, neutralizing antibodies are a key requisite in the fight against viral infections. Patients depleted of antibody‐producing B cells, such as those treated with rituximab (anti‐CD20) for hematological malignancies, lack a fundamental part of their adaptive immunity. Treatment with convalescent plasma appears to be of general benefit in this particularly vulnerable cohort. We analyzed clinical course and inflammation markers of three B‐cell‐depleted patients suffering from COVID‐19 who were treated with convalescent plasma. In addition, we measured serum antibody levels as well as peripheral blood CD38/HLA‐DR‐positive T‐cells ex vivo and CD137‐positive T‐cells after in vitro stimulation with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐derived peptides in these patients. We observed that therapy with convalescent plasma was effective in all three patients and analysis of CD137‐positive T‐cells after stimulation with SARS‐CoV‐2 peptides showed an increase in peptide‐specific T‐cells after application of convalescent plasma. In conclusion, we here demonstrate efficacy of convalescent plasma therapy in three B‐cell‐depleted patients and present data that suggest that while application of convalescent plasma elevates systemic antibody levels only transiently, it may also boost specific T‐cell responses. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results